Astellas Pharma Inc.

TSE:4503 Stock Report

Market Cap: JP¥2.7t

Astellas Pharma Management

Management criteria checks 1/4

Astellas Pharma's CEO is Naoki Okamura, appointed in Apr 2023, has a tenure of 1.75 years. total yearly compensation is ¥461.00M, comprised of 29.5% salary and 70.5% bonuses, including company stock and options. directly owns 0.003% of the company’s shares, worth ¥86.58M. The average tenure of the management team and the board of directors is 5 years and 1.6 years respectively.

Key information

Naoki Okamura

Chief executive officer

JP¥461.0m

Total compensation

CEO salary percentage29.5%
CEO tenure1.8yrs
CEO ownership0.003%
Management average tenure5yrs
Board average tenure1.6yrs

Recent management updates

Recent updates

Astellas Pharma (TSE:4503) Has Announced A Dividend Of ¥37.00

Jan 03
Astellas Pharma (TSE:4503) Has Announced A Dividend Of ¥37.00

Astellas Pharma (TSE:4503) Will Pay A Dividend Of ¥37.00

Dec 04
Astellas Pharma (TSE:4503) Will Pay A Dividend Of ¥37.00

Astellas Pharma's (TSE:4503) Earnings May Just Be The Starting Point

Nov 06
Astellas Pharma's (TSE:4503) Earnings May Just Be The Starting Point

Astellas Pharma Inc. (TSE:4503) Just Released Its Half-Yearly Earnings: Here's What Analysts Think

Nov 01
Astellas Pharma Inc. (TSE:4503) Just Released Its Half-Yearly Earnings: Here's What Analysts Think

Astellas Pharma Inc.'s (TSE:4503) Earnings Haven't Escaped The Attention Of Investors

Oct 15
Astellas Pharma Inc.'s (TSE:4503) Earnings Haven't Escaped The Attention Of Investors

Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

Sep 24
Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

Sep 03
Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

Aug 20
Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

Earnings Beat: Astellas Pharma Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 04
Earnings Beat: Astellas Pharma Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Astellas Pharma's (TSE:4503) Shareholders Will Receive A Bigger Dividend Than Last Year

Jul 26
Astellas Pharma's (TSE:4503) Shareholders Will Receive A Bigger Dividend Than Last Year

Astellas Pharma (TSE:4503) Is Paying Out A Larger Dividend Than Last Year

Jul 11
Astellas Pharma (TSE:4503) Is Paying Out A Larger Dividend Than Last Year

Is Astellas Pharma (TSE:4503) A Risky Investment?

Jun 14
Is Astellas Pharma (TSE:4503) A Risky Investment?

Astellas Pharma's (TSE:4503) Soft Earnings Are Actually Better Than They Appear

May 02
Astellas Pharma's (TSE:4503) Soft Earnings Are Actually Better Than They Appear

Astellas Pharma Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 29
Astellas Pharma Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Why We're Not Concerned About Astellas Pharma Inc.'s (TSE:4503) Share Price

Feb 29
Why We're Not Concerned About Astellas Pharma Inc.'s (TSE:4503) Share Price

CEO Compensation Analysis

How has Naoki Okamura's remuneration changed compared to Astellas Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

JP¥55b

Jun 30 2024n/an/a

JP¥22b

Mar 31 2024JP¥461mJP¥136m

JP¥17b

Dec 31 2023n/an/a

JP¥4b

Sep 30 2023n/an/a

JP¥38b

Jun 30 2023n/an/a

JP¥107b

Mar 31 2023JP¥204mJP¥70m

JP¥99b

Dec 31 2022n/an/a

JP¥136b

Sep 30 2022n/an/a

JP¥149b

Jun 30 2022n/an/a

JP¥118b

Mar 31 2022n/an/a

JP¥124b

Dec 31 2021n/an/a

JP¥120b

Sep 30 2021n/an/a

JP¥119b

Jun 30 2021n/an/a

JP¥101b

Mar 31 2021JP¥236mJP¥70m

JP¥121b

Dec 31 2020n/an/a

JP¥138b

Sep 30 2020n/an/a

JP¥140b

Jun 30 2020n/an/a

JP¥187b

Mar 31 2020JP¥232mJP¥53m

JP¥195b

Compensation vs Market: Naoki's total compensation ($USD2.91M) is above average for companies of similar size in the JP market ($USD1.34M).

Compensation vs Earnings: Naoki's compensation has increased by more than 20% in the past year.

CEO

Naoki Okamura (62 yo)

1.8yrs

Tenure

JP¥461,000,000

Compensation

Mr. Naoki Okamura, BSc, served as Chief Business Officer at Astellas Pharma Inc. since September 2021 until 2022. He served as Executive Vice President at Astellas Pharma Inc. since 2021 until April 1, 202...

Leadership Team

NamePositionTenureCompensationOwnership
Naoki Okamura
President1.8yrsJP¥461.00m0.0032%
¥ 86.6m
Atsushi Kitamura
Senior Executive Officer & CFO2yrsno datano data
Nobue Yasuda
General Manager of Finance & Accounting Departmentno datano datano data
Yoshitsugu Shitaka
Chief Scientific Officer & Senior Managing Executive Officer4yrsno datano data
Catherine Levitt
General Counselno datano datano data
Katsuyoshi Sugita
Chief People Officer3.7yrsno data0.00061%
¥ 16.6m
Stig Ogata
Vice President of Corporate Communications6.8yrsno datano data
Tatjana Dragovic
Senior VP and Head of Ethics & Compliance6.8yrsno datano data
Nobuaki Tanaka
President of Japan Commercial & Senior Corporate Executive8.6yrsno datano data
Jun Kono
Senior Executive Officer & Head of Japan Commercialless than a yearno datano data
Hideki Shima
Chief Manufacturing Officer & Senior Corporate Executive6yrsno datano data
Leticia Delgado-Herrera
VP and Rx+ M&D Head6yrsno datano data

5.0yrs

Average Tenure

Experienced Management: 4503's management team is seasoned and experienced (5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Naoki Okamura
President5.6yrsJP¥461.00m0.0032%
¥ 86.6m
Katsuyoshi Sugita
Chief People Officer1.6yrsno data0.00061%
¥ 16.6m
Takashi Tanaka
Independent Outside Director3.6yrsno datano data
Masahiro Miyazaki
Outside Independent Director1.6yrsno data0.000060%
¥ 1.6m
Kenji Yasukawa
Chairman of the Board7.6yrsJP¥309.00m0.010%
¥ 272.3m
Tomoko Aramaki
Outside Independent Directorless than a yearno datano data
Eriko Sakurai
Independent Outside Director2.6yrsno datano data
Mika Nakayama
Independent Outside Director2.6yrsno datano data
Rie Akiyama
Outside Independent Director1.6yrsno datano data
Yoichi Ohno
Outside Independent Director1.6yrsno datano data
Rika Hirota
Directorless than a yearno datano data

1.6yrs

Average Tenure

63yo

Average Age

Experienced Board: 4503's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 21:06
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Astellas Pharma Inc. is covered by 31 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Koichi MameganoBofA Global Research
Hazim BahariCFRA Equity Research